Cargando…

Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials

Because the human heart has limited potential for regeneration, the loss of cardiomyocytes during cardiac myopathy and ischaemic injury can result in heart failure and death. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Ming, Wang, Richard, Wang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282433/
https://www.ncbi.nlm.nih.gov/pubmed/28194324
http://dx.doi.org/10.1155/2017/9404057
_version_ 1782503320068292608
author Hao, Ming
Wang, Richard
Wang, Wen
author_facet Hao, Ming
Wang, Richard
Wang, Wen
author_sort Hao, Ming
collection PubMed
description Because the human heart has limited potential for regeneration, the loss of cardiomyocytes during cardiac myopathy and ischaemic injury can result in heart failure and death. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients. The ideal candidate donor cell for myocardial reconstitution is a stem-like cell that can be easily obtained, has a robust proliferation capacity and a low risk of tumour formation and immune rejection, differentiates into functionally normal cardiomyocytes, and is suitable for minimally invasive clinical transplantation. The ultimate goal of cardiac repair is to regenerate functionally viable myocardium after myocardial infarction (MI) to prevent or heal heart failure. This review provides a comprehensive overview of treatment with stem-like cells in preclinical and clinical studies to assess the feasibility and efficacy of this novel therapeutic strategy in ischaemic cardiomyopathy.
format Online
Article
Text
id pubmed-5282433
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-52824332017-02-13 Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials Hao, Ming Wang, Richard Wang, Wen Anal Cell Pathol (Amst) Review Article Because the human heart has limited potential for regeneration, the loss of cardiomyocytes during cardiac myopathy and ischaemic injury can result in heart failure and death. Stem cell therapy has emerged as a promising strategy for the treatment of dead myocardium, directly or indirectly, and seems to offer functional benefits to patients. The ideal candidate donor cell for myocardial reconstitution is a stem-like cell that can be easily obtained, has a robust proliferation capacity and a low risk of tumour formation and immune rejection, differentiates into functionally normal cardiomyocytes, and is suitable for minimally invasive clinical transplantation. The ultimate goal of cardiac repair is to regenerate functionally viable myocardium after myocardial infarction (MI) to prevent or heal heart failure. This review provides a comprehensive overview of treatment with stem-like cells in preclinical and clinical studies to assess the feasibility and efficacy of this novel therapeutic strategy in ischaemic cardiomyopathy. Hindawi Publishing Corporation 2017 2017-01-17 /pmc/articles/PMC5282433/ /pubmed/28194324 http://dx.doi.org/10.1155/2017/9404057 Text en Copyright © 2017 Ming Hao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hao, Ming
Wang, Richard
Wang, Wen
Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title_full Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title_fullStr Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title_full_unstemmed Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title_short Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials
title_sort cell therapies in cardiomyopathy: current status of clinical trials
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282433/
https://www.ncbi.nlm.nih.gov/pubmed/28194324
http://dx.doi.org/10.1155/2017/9404057
work_keys_str_mv AT haoming celltherapiesincardiomyopathycurrentstatusofclinicaltrials
AT wangrichard celltherapiesincardiomyopathycurrentstatusofclinicaltrials
AT wangwen celltherapiesincardiomyopathycurrentstatusofclinicaltrials